In Silico Cell For TB Drug Discovery, University Of Surrey, UK

A team of researchers from the University of Surrey have completed the
first genome-scale model of the microbe that causes tuberculosis. The
model may be a highly useful tool to identify new drug targets and
design new vaccines.


Tuberculosis remains one of the biggest killers in the world today being
responsible for nearly ten million cases and one and a half million
deaths each year. New strains are emerging that are resistant to all
current front-line anti-tuberculous drugs so new drugs are urgently
needed. However, little is known about the metabolism of the TB bacillus
and, because of its slow growth, experiments take a very long time.


The Surrey group hopes to speed up the drug discovery process by
building an in silico model of the agent that causes TB: a virtual TB
bacillus. This model was constructed using information from the entire
genome sequence of the pathogen and uses mathematical equations to model
the flow of nutrients through the cell. The model is extremely complex,
handling 848 different biochemical reactions and 726 genes. The Surrey
team showed that the model successfully simulates many of the peculiar
properties of the TB bacillus and identifies the drug targets of known
anti-tuberculous drugs. But unlike the biological organisms, the in
silico TB bacillus grows in nanoseconds so experiments that would
normally take months can be performed in minutes. The group hope that
the in silico model may be used to identify new drug targets,
particularly those capable of killing persistent bacilli.


The work is published in the high-profile journal Genome Biology and
describes not only the model but, for the first time, makes an in silico
model available to other researchers via an interactive website.
Researchers will be able to perform experiments on the virtual TB
bacillus from a beach in Bombay or a mountaintop in Malawi. It is hoped
that the availability of this novel research tool will stimulate new
approaches to control of this deadly pathogen.


The University of Surrey is one of the UK's leading professional,
scientific and technological universities with a world class research
profile and a reputation for excellence in teaching and research.
Ground-breaking research at the University is bringing direct benefit to
all spheres of life - helping industry to maintain its competitive edge
and creating improvements in the areas of health, medicine, space
science, the environment, communications, defence and social policy.
Programmes in science and technology have gained widespread recognition
and it also boasts flourishing programmes in dance and music, social
sciences, management and languages and law. In addition to the campus on
150 hectares just outside Guildford, Surrey, the University also owns
and runs the Surrey Research Park, which provides facilities for 140
companies employing 2,700 staff.


The Sunday Times names Surrey as 'The University for Jobs' which
underlines the university's growing reputation for providing high
quality, relevant degrees.


surrey.ac.uk